
Reasons for Research





Why Advocacy Matters



2012 ANNUAL REPORT



Contents

- Letter from the Chair and President
- Save Research Campaign
 - PAGE 5 Unsung Heroes
- Your Candidates—Your Health

Page 7 Post-election Briefing

PAGE 8 Global Health

Page Public Health Thank You Day

PAGE 10 UCSF Briefing

INSERTS

Financials, Member List



Research!America is the nation's largest 501(c)(3) alliance working to make research to improve health a higher national priority. Research!America's member organizations together represent the voices of more than 125 million Americans. Our public opinion data, advocacy programs and publications reach the public and decision makers to help advance medical health and scientific research.

National Health Research Forum

PAGE 14 2012 Awards

PAGE 15 Donors and Staff

PAGE 16 Board of Directors

Reasons for Research: Why Advocacy Matters

Biomedical research improves both Americans' health and America's economic health. Policies that support both public and private sector research are critical to bringing improved therapies to patients more quickly and maintaining American competitiveness. As advocates, we must make certain our elected officials know the essential role research plays in all of these areas. In 2012, Research! America honored eight outstanding advocates for their reasons to further research at the Advocacy Awards dinner and the Garfield Economic Impact Awards reception.

Reducing infant mortality

AMALIA MILLER, PHD

Associate Professor,
University of Virginia



New ideas, new treatments, new jobs and new cures SEN. BARBARA MIKULSKI



Technology offers cost-saving solutions DONALD LINDBERG, MD Director, National Library of Medicine





200 cancers will
collectively become
the number-one killer
MARGARET FOTI, PHD, MD (H.C.)
CEO, American Association
for Cancer Research



President, CEO and Founder, Myelin Repair Foundation






One in 13 children have food allergies
MARY JANE MARCHISOTTO
Executive Director,
Food Allergy Initiative



Saving lives in dramatic and world-changing fashion CATHERINE TUCKER, PHD Associate Professor, Massachusetts Institute of Technology



Investing in research is a strategic decision to advance noncommercial discovery that becomes the basis for private sector development of new medical treatments.

JOHN EDWARD PORTER



Research is part of the solution to tackling rising health care costs driven by diseases like Alzheimer's, cancer and Parkinson's.

MARY WOOLLEY
PRESIDENT AND CEO

Reasons for Research

Healthier Lives, Stronger Economy, Global Impact: Why Advocacy Matters

INDIVIDUALS FROM ALL WALKS OF LIFE DEPEND ON THE PROMISE OF RESEARCH

- for their health, their family's health and prosperity, and their future in an economically thriving nation. Those dreams and aspirations could be dashed with policy decisions that would cripple our nation's research enterprise. In a climate dominated by deficit reduction, policy makers are under pressure to reduce all government spending, even if it slows medical progress and jeopardizes job growth and our global competitiveness. Yes, tough decisions must be made to put the nation's fiscal house in order, but cutting funding for research won't solve our fiscal woes. Indeed, investing in research is a strategic decision to advance noncommercial discovery that becomes the basis for private sector development of new medical treatments. Policy makers must refuse to endanger both public and private sector contributions to our nation's unrivaled research enterprise. In partnership with our members, we carry this message in our Save Research campaign, launched in November 2012. This intensified advocacy campaign, which includes Capitol Hill visits, advertisements, sign-on letters for congressional leadership, social media strategies, and Call-In and Advocacy Alert Days has successfully brought together stakeholders in the research community with leading patient advocates to speak with one voice to protect the research pipeline, from bench to bedside. The message is being heard by media and by Washington decision makers, but there is more to do to achieve our goal of making research for health a top national priority.

Research! America's 2012 Advocacy Award winners and Garfield Award winners profiled in this report are examples of exceptional researchers, scientists and others who recognize the power of advocacy in shaping public policy and improving quality of life. Their advocacy has raised public awareness about the value of biomedical and health economics research and the ensuing societal benefits; it is a model for us all. Americans understand that research is part of the solution to tackling rising health care costs driven by diseases like Alzheimer's, cancer and Parkinson's. They agree that biomedical and health research must be a national priority. Our commissioned public opinion polls amply illustrate these points and more — highlighting Americans' concerns about stagnant and reduced funding levels for the federal health agencies and reinforcing the importance of eliminating barriers to innovation in the private as well as public sectors.

We extend special thanks to our members, partners and contributors for their support, recommendations and enthusiasm in elevating the importance of research as a health and economic driver at this critical time. Please continue to work with us in 2013 as we engage and cultivate more champions for our nation's research ecosystem. Let's fulfill the dreams of families across the globe and those of future generations!

The Honorable John Edward Porter

Chair

Mary Woolley
President and CEO

With research funding at risk, Research! America took the message to the public.

Save Research Campaign

Research! America's advocacy efforts intensified as the fiscal cliff and sequestration posed grave threats to federally funded research. The result — the Save Research Campaign, with 142 active partners — utilized advertising, media coverage, grassroots activities and advocacy to tell Congress and the White House: We Need Cures, Not Cuts!

That message got attention. In addition to op-eds and letters to the editor in publications from coast to coast, the advertising itself caught the media's attention, including *The New York Times, The Hill, Science, National Journal* and the Associated Press. Tens of thousands of emails were sent to Congress and the administration, and Research! America participated in more than 60 meetings on Capitol Hill in conjunction with the Save Research Campaign. A letter sent to congressional leadership garnered signatures from 145 organizations and distinguished individuals; the letter was subsequently sent to all Members of Congress.



In new media, the campaign reached nearly 50,000 people through social media, and nearly 2,500 visited the campaign's website, www.saveresearch.org.

As the debate over the country's fiscal challenges continued, so too did the Save Research Campaign. A second phase of the campaign began in early 2013 as Congress and the administration tackled sequestration, the federal budget and the debt ceiling.

Resolutions to the issues of federal debt and deficit seem far off. In the interim, Research! America will continue to remind elected officials and the public that cutting research funding and enacting other policies that inhibit innovation are counterproductive not only to American health but also the economy and global competitiveness.



In new media, the campaign reached nearly 50,000 people through social media. Nearly 2,500 visited the campaign's website.



"A 10% increase in the adoption of basic EMRs can reduce infant mortality by 16 deaths per 100,000 births."

"The U.S. has one of the highest infant mortality rates among developed nations, despite the largest per-capita expenditures on health care. One potential explanation for this disparity is that coordination efforts by centralized health authorities have led to a more systematized approach to the adoption of health care IT in other comparable industrialized nations. Electronic medical records (EMRs) and other health care IT improvements offer a potential way to reduce this death rate, by improving access to patient records, standardizing treatment options and improving monitoring ... Our panel estimates [suggest] that a 10% increase in the adoption of basic EMRs can reduce infant mortality by 16 deaths per 100,000 live births.

We find further evidence that health care IT adoption has the most beneficial effects for birth outcomes for historically disadvantaged groups and there is no evidence that the gains to EMRs are focused on women from higher socio-economic backgrounds. Rough cost-effectiveness calculations suggest that health care IT is associated with a cost of \$531,000 per infant saved. These findings provide an empirical basis for government policy intervention to hasten the diffusion of health care IT."

AMALIA MILLER, PHD

2012 GARFIELD ECONOMIC IMPACT AWARD WINNER

EXCERPTED FROM THE 2012 GARFIELD ECONOMIC IMPACT AWARD-WINNING PUBLICATION WITH CATHERINE TUCKER, PHD



Unsung Heroes

or the third straight year, the Campaign for Public Health Foundation feted its Unsung Heroes of Public Health with a ceremony in Washington, DC. The 2012 event was held in the Rayburn House Office Building on Capitol Hill and sponsored by Kaiser Permanente Program Offices Fund for Community Benefit at the East Bay Community Foundation and GlaxoSmithKline.

The honorees included Matt McDaniel, Cities Readiness Initiative coordinator for Shelby County (TN) — which includes Memphis — who won the Wavemaker Award; and Gabe Norwood, director of community engagement for the Finger Lakes Health Systems Agency, who won the Rock in the Pond Award. The awards are meant to call attention to those making a difference on the front lines of public health across the nation. McDaniel was honored for his work in helping Greater Memphis respond to natural disasters, disease outbreaks and other events. Norwood was honored for his work in lowering chronic and infectious disease rates among at-risk populations in and around Rochester, NY.

Anna Gorman, health writer for the Los Angeles Times, won the Excellence in Media Award, which aims to celebrate a journalist whose factual, research-based reporting helps inform the public.

The evening ceremony capped a day of meetings on Capitol Hill. Among those in attendance were Reps. Jim McGovern (D-MA) and Lucille Roybal-Allard (D-CA), co-chairs of the Congressional Study Group on Public Health. McGovern, Roybal-Allard and Rep. Phil Roe, MD (R-TN) served as honorary co-chairs for the event.



The Campaign for Public Health Foundation Executive Director Karl Moeller is flanked by winners Anna Gorman and Matt McDaniel

"Coming to NLM in 1984 brought together all of my interests in research and technology advocacy. When I arrived at the Library, we were indexing the medical literature manually. We gradually brought computers into the process and now it's almost completely automated. Physician users of Medline were given increasingly useful methods with which to call in from their office or home computers: Grateful Med, Lonesome Doc, then PubMed and access to many genomic databases. We work toward ever closer relationships between librarians, health professionals, engineers and the public. Advocacy by Research! America is essential.

Though the discussions are still in preliminary stages, I am now advocating the use of technology, including IBM's Watson, to develop logic that can answer the thousands of health-related questions NLM gets from patients, their families and the public on a daily basis. The questions we get are much harder to answer than I originally guessed.

Ultimately, answering the public's health-related questions is going to help reduce the cost of care and get people to choose a lifestyle that is to their benefit. The activated patient is the critical part of health preservation."

"The activated patient is the critical part of health preservation."

DONALD LINDBERG, MD

2012 ADVOCACY AWARD WINNER

"I'm on the side of cures and I'm on the side of supporting America's continued innovation in the life sciences – that's why I have fought for years to increase our federal investment in research. At a time of fiscal constraint, we must find opportunities where we can invest smartly – and I can think of no better place to do that than by supporting the research that works to improve the health of our nation. Smart funding leads to smart research that leads to new ideas, new treatments, new jobs and new cures. That's why I've made research and innovation one of my top priorities and why it will remain a top priority in the years to come."

SENATOR BARBARA MIKULSKI (D-MD)

2012 ADVOCACY AWARD WINNER




The Run-up to the 2012 General election,
Research! America once again conducted its signature voter education initiative, *Your Candidates-Your Health*. We asked candidates running for federal office to respond to a questionnaire that asked them to detail their views on public and private sector research; American competitiveness; and federal agencies conducting research to improve health, among other topics.

Research! America received more than 150 responses from incumbents and challengers alike, including President Barack Obama and Republican challenger Mitt Romney. Among the Members of the 113th Congress to respond were: Sen. Tammy Baldwin (D-WI); Sen. Ben Cardin (D-MD); Rep. Dan Benishek, MD (R-MI); Rep. Joseph P. Kennedy III (D-MA); Rep. Ed Markey (D-MA); Rep. Aaron Schock (R-IL); Rep. Chris Van Hollen (D-MD); and Rep. Don Young (R-AK).

In analyzing the responses, several areas of agreement among respondents were discovered: 95% of Democrats and 94% of Republicans said that research is part of the solution, not part of the problem, to rising health care costs; and 99% of Democrats and 85% of Republicans said health research sponsored by the National Institutes of Health should be a higher national priority.






"Smart funding leads to smart research that leads to new ideas, new treatments, new jobs and new cures."

More than Half of Americans Willing to Pay Tax for Research


Would you be willing to pay \$1 per week more in taxes if you were certain that all of the money would be spent on additional medical research?



SOURCE: A RESEARCH! AMERICA POLL OF U.S. ADULTS CONDUCTED IN PARTNERSHIP WITH ZOGBY ANALYTICS IN DECEMBER 2012.

WIDE MAJORITY BELIEVES
RESEARCH IS KEY TO REDUCING
HEALTH CARE COSTS

How important is medical research to reducing health care costs?



Source: A Research! America poll of U.S. adults conducted in partnership with Zogby Analytics in December 2012.

Post-election Briefing

PAYS AFTER THE 2012 GENERAL ELECTIONS, Research! America partnered with the American Association for the Advancement of Science and the American Cancer Society Cancer Action Network for a panel discussion on what the elections meant for the fate of medical research.

Research! America President and CEO Mary Woolley moderated the discussion among three panelists: *National Journal Daily* editor Matthew Cooper; Research! America Board member and former Congressman Kweisi Mfume; and Research! America Chair and former Congressman John Edward Porter.

The panelists acknowledged that reducing the country's debt and federal deficit would be the top priority of the 113th Congress. But without a clear picture on how Congress would deal with expiring tax cuts and scheduled tax increases, there was likewise no clear indication on how important medical research would be to the new Congress.


The panelists did see some good news for research advocates. Mfume believed

that Congress would again pass the R&D tax credit, while Cooper said that he saw an administration that is very supportive of science and technology. "It's an itch they want to scratch," Cooper said.

The event was held at the AAAS building in downtown Washington, DC. In addition to the panel discussion and overview of the Your Candidates—Your Health initiative, the event also celebrated the 2012 Garfield Economic Impact Award winners, Amalia R. Miller, PhD, and Catherine E. Tucker, PhD.



Kweisi Mfume, Mary Woolley, Matthew Cooper and John Edward Porter



"Two hundred diseases
we call cancer are
collectively on track
to soon become the
number-one killer."

"We must continue to work very hard to tell our story to the policy makers, the story of how the 200 diseases we call cancer are collectively on track to soon become the number-one killer among all human diseases. Of how, without adequate federal support, the promising scientific ideas for stemming the tide of cancer will sadly go unpursued ... It's really a great blessing to be able to work in the cancer field and to know that, in some small way, my work is helping people.

We must never forget our patients. Our patients are waiting, and they're depending on us to do better. And they bring us their suffering, and they bring us the need to move forward. We must bring them this amazing scientific discovery that is happening. We must bring all of that to their bedsides as rapidly as possible ... As we work toward this goal, I want to say that we bring this positive result, this wonderful science that we have today that we can translate to the patient, that we continue to advocate for medical research with the goal of making it a higher national priority."

MARGARET FOTI, PHD, MD (H.C.)
2012 ADVOCACY AWARD WINNER

"I think we can, in a sense, use media to broaden the peer review process. I think that this is a very exciting part: broaden that peer review process so that everyone really has a voice. It can also create a more inclusive, contributing community for scientists and researchers all over the world. You never know where the next great development, the next great research is going to come from; I think media can help give a voice to lots of people, lots of labs, lots of contributors — right in this room and anywhere around the world. And I think they can make all of that happen much faster.

If someone's confronting a medical illness, you want to get as much content, as much knowledge that's credible as quickly as possible. I think media can help with that. And I think I also speak on behalf of all people that work in the medical media to say that we're truly privileged to do what we do, but we also realize that with our jobs comes tremendous responsibility as well."

SANJAY GUPTA, MD 2012 ADVOCACY AWARD WINNER



"You never know where the next great development, the next great research is going to come from."

Global Health

WHETHER THROUGH EVENTS, PUBLICATIONS, advertising or outreach, Research! America's advocacy showed the promise and benefits of global health R&D — both of which directly impact Americans.

With widely attended events in New York City and Houston, Research! America made clear the considerable economic and health impacts of global health R&D. In New York, Rep. Nita Lowey (D-NY) made remarks prior to a panel discussion on public-private partnerships and the economic benefits of global health R&D in New York. Noted global health figure Laurie Garrett moderated the panel. In Houston, a daylong program focused on the hidden burden of neglected tropical diseases, which represent a particular threat in South Texas.

Fact sheets and other publications also helped bring attention to the importance of global health R&D. A series of fact sheets explained the threat of neglected tropical diseases to populations in the U.S. and around the world; a separate fact sheet showed how one NTD, Chagas disease, impacts Americans and spotlights the research being done to combat it. Research!America's list of top 10 reasons to invest in global health was also widely disseminated within the community.

That message was made clear to the general public in targeted advertising: Four ads appeared in Politico and on mass transit in the Washington, DC, area. Each advertisement highlighted the success — and sometimes unexpected payoff — of investing in global health research.

Research! America took that message to Capitol Hill too; 45 meetings with Members of Congress or their staffs helped reinforce the message that global health R&D is a sound investment, and one whose benefits are realized inside America's borders.



Public Health Thank You Day

RESEARCH! AMERICA and its partners invited members of the public to honor public health workers on the Monday before Thanksgiving. Each year, Public Health Thank You Day gives us a chance to thank those who work to protect the public's health every day in ways large and small.

The message was spread to audiences around the country: It was featured on a blog post by Minnesota Commissioner of Health Edward Ehlinger, MD, MSPH; it was celebrated at an event at the University of South Florida College of Public Health; and it was the impetus for a message from the Peoria (IL) City/County Health Department. Social media such as Twitter and Facebook also helped spread the message of Public Health Thank You Day.



"Several months after the Food Allergy Initiative (FAI) received Research! America's Paul G. Rogers Distinguished Organization Advocacy Award, we merged with the nation's other leading food allergy organization, the Food Allergy & Anaphylaxis Network (FAAN). The mission of our new organization, Food Allergy Research & Education (FARE), is to ensure the safety and inclusion of individuals with food allergies while relentlessly seeking a cure.

This is a crucial time in the national discourse around food allergies. Widely regarded as a growing public health issue, up to 15 million Americans now have food allergies, including 1 in every 13 children — roughly two in every classroom. Nearly 40% of these children have already experienced a severe or life-threatening reaction.

Working with concerned legislators and dedicated parents nationwide, FARE has been able to increase the federal investment in research from virtually zero to nearly \$28 million today. In addition, we have successfully advocated for key federal, state and local initiatives, including access to lifesaving epinephrine in schools and managing food allergies in schools, camps and restaurants. We have gained tremendous ground over the past two decades, and our advocacy initiatives are vital to maintaining our momentum."

MARY JANE MARCHISOTTO

"... up to 15 million

Americans now have food

allergies, including one
in every 13 children."




"From the patient perspective, the time spent on waiting for a cure can be discouraging ... As a result, many patients are left waiting for new effective treatments or cures. Patient advocates are critical to bringing a personal perspective to disease, helping scientists view science beyond an experiment or publication of a peer-reviewed study — science is critical to developing new treatments that can transform lives.

At the Myelin Repair Foundation, my personal experience as a patient inspires me to expand the scope of medical research to impact disease and produce new treatments efficiently. Given my background as a business consultant and serial entrepreneur for over 25 years, the Myelin Repair Foundation tackles the challenges facing medical research and drug development head on. The barriers can seem overwhelming — issues arise from the academic scientific lab bench to clinical trials — but these are challenges, I learned, that are not impossible to overcome. Advocates for patient-oriented research bring a unique personal perspective to drive promising science forward to develop new effective treatments for disease, changing patient lives for the better."

SCOTT JOHNSON
2012 ADVOCACY AWARD WINNER

"Advocates for patientoriented research
bring a personal
perspective to drive
science forward."



UCSF Briefing

IN JUNE, RESEARCH! AMERICA AND ITS PARTNERS hosted a breakfast briefing to discuss data that is just now emerging as a result of the country's large national investment in genomics during the past two decades. The briefing, titled "The Genetic Revolution ... How It Will Help Patients, When, And How Patients Can Help," was sponsored by Research! America; the University of California, San Francisco; The Kaiser Permanente Research Program on Genes, Environment and Health; and The Robert Wood Johnson Foundation.

The briefing was held at the Kaiser Permanente Center for Total Health, blocks away from the U.S. Capitol in Washington, DC.

In attendance was senior-level staff from several members of the California congressional delegation, as well as representatives from patient advocacy, government, academic, philanthropic and media organizations. They heard a presentation from lead co-investigators Neil Risch, PhD, director of the UCSF Institute for Human Genomics, and Catherine Schaefer, PhD, director of The Kaiser Permanente Research Program on Genes, Environment and Health. Meredith Wadman, biomedical reporter for *Nature*, moderated the discussion.

The study performed by Risch and Schaefer was funded by a Grand Opportunities grant from the National Institutes of Health; the grant sought to link genetics to health records across a diverse population. More than 150,000 genetic samples from patient-volunteers have been genotyped and coordinated with up to 40 years of electronic health records.


Risch and Schaefer believe their work will accelerate health and medical research. Moreover, it will help patients by introducing genetics to help determine therapeutic options. That means more quickly identifying the best medicines for the individual and less of a trial-and-error approach.

U.S. WORLD LEADERSHIP MATTERS

Which is closer to your view?

Statement A: Some people say it is important for U.S. economic competitiveness and prosperity that our nation continues to lead in the sciences.

Statement B: Other people say that it is now other countries' time to lead in the sciences.



Source: A Research! America poll of likely voters conducted in partnership with Zogby Analytics in March 2012.







"The paper that we received the [award] for was based (in part) on my experience of suffering twin-to-twin transfusion syndrome when I was pregnant with my daughters. This is a disease that just a decade or so ago claimed the lives of nearly 90% of babies that suffered it. Now, due to pioneering research, it can be treated through in-utero surgery.

[Advocacy for medical research] is important because the effects of investing in medical research are often long-term. In 10 years we might be able to save lives in a dramatic and world-changing fashion. However, the investment's good effects will not be seen in the immediate six weeks."

CATHERINE TUCKER, PHD
2012 GARFIELD ECONOMIC IMPACT AWARD WINNER

National Health Research Forum 2012

Each year, Research! America convenes leaders from government, industry, academia, voluntary health organizations and the media to discuss the current state of the research enterprise and how today's policies affect tomorrow's discoveries.



"I think one of the roles of media is to be skeptical, is to ask those tough questions, is to look to see in the setting of [public-private collaborations] and what the rules are on that collaboration ... We're not going to get anywhere without a strong public-private collaboration, but it has to be very, very clear. And it isn't always."

RICHARD BESSER, MD, CHIEF HEALTH AND MEDICAL EDITOR, ABC NEWS

"Research both helps people live longer lives by all of the work that's done in drug discovery, new therapies and things that impact families, patients, caregivers, every single day. And research boosts the economic engine of every community that hosts academic institutions in this country."







"I think it's incumbent upon all of us, because we've all used this word, ecosystem, to make sure that students, young people, all of us who are in the industry understand that it is not only interdependent, but it is necessary, beneficial and can be rewarding no matter where you are in that process ... All of it feeds together. And it shouldn't be competitive, but rather it should be mutually supportive. We don't do enough of that, in my opinion."

JOHN CASTELLANI, PRESIDENT AND CEO, PHRMA

"Preventing health care-associated infections is reducing health care costs by billions of dollars a year. And yet there are billions more that we haven't yet reduced, and we need to figure out how to. Take immunization: Every dollar we spend vaccinating children saves \$3 of health care costs and \$10 for the society as a whole ... We have much more to do in prevention, and it is the best buy."







"You don't just take a publication in literature that says that something might interfere with the disease pathogenesis and then start using it in medical care. It has to be studied to make sure that in fact it is safe and effective ... It matters to every individual that this kind of research is done within the walls of FDA or it's done in collaboration with others."

MARGARET HAMBURG, MD, COMMISSIONER, FOOD AND DRUG ADMINISTRATION

"There's been a paradigm shift; we now see academic institutions as being drivers and engines for innovation. So we need this partnership with industry. I think we bring all of this together for the presidential election, for the campaign, and we really try to put aside these emotional issues and just focus on the facts and the outcomes."







"Why we should invest in research in the United States is it makes the country competitive, and if we don't do it, it will move elsewhere. It's a high-risk enterprise; it should also be a high-reward enterprise ... Until people understand that it is high risk and there are no guarantees and there needs to be an incentive for this, then we will lose our competitive edge, and that is why I think the government needs to incentivize."

JACK WATTERS, MD, VICE PRESIDENT FOR EXTERNAL MEDICAL AFFAIRS, PFIZER INC





"Any one of us here can go into the offices of our Members of the House or Senate and speak to them about the significance of health care research dollars, be it from one of the agencies or in some other way. And it's very persuasive ... It can happen, but it's our responsibility; it's not just going to happen because we sort of wish it to happen. It's going to happen with a lot of good, hard work."

THE HONORABLE MICHAEL N. CASTLE

"You hear people coming from all over the world to come to the U.S. because we're doing just fantastic, breakthrough things that absolutely you can't get anywhere else. At the same time, my dad is readmitted to the hospital because he's on a blood thinner, and our nurse calls his wife and says, 'Give him two.' Milligrams? Pills? One meant one, the other heard the other. And this kind of thing goes on every single day of the week."



CAROLYN CLANCY, MD, DIRECTOR, AGENCY FOR HEALTHCARE RESEARCH AND QUALITY



"If we lose this generation of young researchers because they get discouraged by this downturn, they're not going to come back. So probably the greatest fault line is simply that we are not providing the kind of resources, across the board, that investigators could use to make these next discoveries because we are in a different financial circumstance."

FRANCIS COLLINS, MD, PHD, DIRECTOR, NATIONAL INSTITUTES OF HEALTH

"When you look at the broadest measures possible—household income, longevity — it just seems like we're not making that much progress there. And so you go to a childhood leukemia ward — it's like one of the most inspiring things you can possibly imagine, because you're literally seeing people who would not have been alive that long ago, and they're going to go on to these wonderfully productive lives. And it is because of scientific advance."



DAVID LEONHARDT, WASHINGTON BUREAU CHIEF, THE NEW YORK TIMES



"If you look at the burden of disease and the burden on society, it's huge, and I'll use Alzheimer's as an example. One of the things that's critically important is understanding when do you get the patient in, how do you get the patient in, do you treat them in different ways? ... It's not about just a medicine; it's about dealing with the caregivers, dealing with the system that's in place to support that individual, dealing with the stigma associated."

SHERI S. McCoy, MSc, FORMER VICE CHAIRMAN, JOHNSON & JOHNSON

"[With Alzheimer's disease,] I don't think we've ever been at a point in time when we have the tools in hand and the opportunity to make a huge impact on a disease that has enormous economic consequences, human and social consequences, and so forth ... I think we're all reluctant to predict that we'll have great treatments for Alzheimer's disease in the next five years, but I just don't see things as gloomily as are outlined here."



LARRY SHAPIRO, MD, EXECUTIVE VICE CHANCELLOR FOR MEDICAL AFFAIRS AND DEAN OF THE SCHOOL OF MEDICINE, WASHINGTON UNIVERSITY IN ST. LOUIS



"When you fund high-quality science on the cutting edge by bringing the right people and the right ideas, you will create economic value ... And if you look at the GDP of these enterprises that are highly successful in relation to the investment, it's many, many times over ... This is what contributed to the economic leadership, the military leadership, the defense leadership of this country. If we had asked short-term questions 30, 40 years ago, we would not be where we are today."

SUBRA SURESH, MS, ScD, DIRECTOR, NATIONAL SCIENCE FOUNDATION

2012 Research! America Awards

Advocacy Awards

Research!America's 17th annual Advocacy Awards dinner celebrated the people whose advocacy and leadership made a difference. The event, held at the Andrew W. Mellon Auditorium in downtown Washington, DC, and its high-level audience paid tribute to the winners and all they had done to promote research to the public and policy makers.



Martha Hill, PhD, RN; Georges Benjamin, MD; Francis Collins, MD, PhD; Sen. Barbara Mikulski (D-MD); and Patricia Grady, PhD, RN

Garfield Economic Impact Award

Each year, Research! America honors a publication by early-career researchers that demonstrates the economic value of medical research. The 2012 Garfield Economic Impact Award, named for noted scientist Eugene Garfield, PhD, was awarded to Amalia Miller, PhD, and Catherine Tucker, PhD. They received the award at the American Association for the Advancement of Science building in downtown Washington, DC.



Garfield Economic Impact Award winners Catherine Tucker, PhD, and Amalia Miller, PhD, with Research!America Board member Mark McClellan, MD, PhD



The Honorable Michael Castle and Carolyn Clancy, MD



Surgeon General Regina Benjamin, MD, and Sanjay Gupta, MD



The Honorable Patrick Kennedy

2012 Donors

VISIONARIES

\$100,000+

Johnson & Johnson

Pfizer Inc

CHAMPIONS

\$50,000-\$99,999

Burroughs Wellcome Fund Howard Hughes Medical Institute

Lilly

Ann Lurie

Merck & Co., Inc.

Sanofi

United Health Foundation

PARTNERS

\$25,000-\$49,999

Abbott Laboratories

Alzheimer's Association

American Medical Association

Amgen

Endo Health Solutions

Food Allergy Initiative

Geoffrey Beene Foundation

GlaxoSmithKline

Gordon and Llura Gund Foundation

Hogan Lovells US LLP

Johns Hopkins University

Pharmaceutical Research and Manufacturers of America (PhRMA)

Rosenfeld Heart Foundation

Society for Neuroscience

UnitedHealth Group

Whitehead Charitable Foundation

Whitehead Institute for Biomedical Research

INNOVATORS

\$10,000-\$24,999

Alexandria Real Estate Equities

American Association for Cancer Research

American Cancer Society Cancer Action Network American Heart Association

American Society for Bone and Mineral Research

Association of American Universities

Battelle

Baylor College of Medicine

The Dana Foundation

Duke University Medical Center

Emergent BioSolutions

Genentech, Inc.

Illumina, Inc

INFOCAST

Ann and Robert H. Lurie Foundation

Mayo Clinic

McKesson Specialty Health

Mvlan

NewYork-Presbyterian Hospital

Northeast Ohio Medical University

Partners Healthcare System, Inc.

Raymond and Beverly Sackler Fund

for the Arts and Sciences United for Medical Research

University of California, Los Angeles

University of California,

San Francisco

University of Maryland, Baltimore

University of Maryland Medical

The University of Texas M.D.

Anderson Cancer Center

Weill Cornell Medical College Susan Whitehead

Mary Woolley

ADVOCATES \$1,500-\$9,999

AcademyHealth

Tenley E. Albright, MD

The Allen Institute for Brain Science

American Association of Colleges

of Pharmacy

American Cancer Society

The Annie E. Casev Foundation

Constellation Energy Group

Cryer Health LLC

Danaher Corporation

Susan Dentzer

Faegre Baker Daniels

FasterCures. The Center for Accelerating Medical Solutions

Friends of Cancer Research

Jay A. Gershen, DDS, PhD

Mary J. C. Hendrix, PhD

and Chuck Craft

Evan Iones

Jackie Lovelace Johnson

Elizabeth Baker Keffer

The Honorable Patrick Kennedy

Debra Lappin, JD

Alan I. Leshner, PhD

The Leukemia & Lymphoma Society

LUNGevity Foundation

Lupus Foundation of America

March of Dimes Foundation

Myelin Repair Foundation

Elizabeth Nabel, MD

 $National\ Multiple\ Sclerosis\ Society$

Herbert Pardes MD

Parkinson's Action Network

Edward E. Penhoet, PhD

The Honorable John Edward Porter

Jeanne and Sanford Robertson

The Rockefeller Foundation

Susan Delaney Rodger

Science Debate, Inc.

Larry J. Shapiro, MD

John R. Seffrin, PhD Samuel C. Silverstein, MD

Stanford University School of

Medicine

The Honorable Louis Stokes

Arthur D. Ullian

Van Andel Research Institute

Vitality Communications

George Washington Cancer Institute

Washington University School of Medicine in St. Louis

Jack Watters, MD

Drs. Elias and Nadia Zerhouni

Zogby Analytics

SUPPORTERS

\$500-\$1,499

Alliance for Aging Research

American Federation for Medical Research

American Public Health Association

American Society of Tropical

Medicine and Hygien Association of Schools of

Public Health

Arizona State University

Dennis A. Ausiello, MD

The Baltimore Family Fund

Nancy Brown

Roger J. Bulger, MD

The Honorable Michael N. Castle

The CFIDS Association of America

Victor Dzau MD

Joseph M. Feczko, MD Feinstein Institute for Medical

Research

Foundation for the National

Institutes of Health Genetic Alliance

Lovelace Respiratory Research

Institute

Shahin Mafi

Lucinda L. Maine, PhD, RPh

The Honorable Kweisi Mfume

Sudip S. Parikh, PhD William A. Peck, MD

Barbara Redman, PhD, FAAN, RN

Rebecca Rogers Mitchel Savare PhD

Carol R. Scheman

M. Roy Schwarz, MD Laing Rogers Sisto

The Honorable Louis W. Sullivan,

Texas Biomedical Research Institute

Research! America Staff

Mary Woolley, President

and CEO Barbara Love, Executive

Assistant to the President

ADMINISTRATIVE Michael Coburn, Chief Operating

Officer Aimée Lefever. Office Manager

Brooke Williams, Staff Accountant

Communications

Anna Briseño.

COMMUNICATIONS Suzanne Ffolkes, Vice President,

Communications Specialist

Brian Hunsicker.

Communications Specialist

Glorymar Rivera, Senior

Communications Associate Megan Kane, Communications

DEVELOPMENT AND MEMBERSHIP

Carol Kennedy, Senior Director,

Development Assistant

Kyndra Fuller, Manager,

Membership Development

Development and Membership $\textbf{Ted Brasfield,} \, \text{Membership } \& \,$

POLICY, PROGRAMS AND OUTREACH

Ellie Dehoney, Vice President, Policy and Programs

Chris Bennett, Senior Program Manager, Global Health R&D

Max Bronstein, Director of Science Policy Jennifer Chow, Director of Global Health R&D and Public

Alexandra Frank, Senior

Health Advocacy

Program Manager, Global Health R&D and Public Health Advocacy Jordan Gates, Administrative Coordinator, Policy and Programs

BURROUGHS WELLCOME INTERNS AND FELLOWS

Anurupa Dev, PhD Rahul Kale

Mia Lowden, PhD

Adam Katz

Alka Malhotra, PhD Jessica Phoumindr GLOBAL HEALTH R&D

ADVOCACY INTERN Megan McCloskey

15

Research! America Leadership

OFFICERS



*Hon. John Edward Porter CHAIR Hogan Lovells US LLP U.S. Representative.

1980-2001



*Martha N. Hill, PhD, RN VICE CHAIR Dean of the School of Nursing, and Professor of Nursing, Medicine & Public Health,

Johns Hopkins University



*Mary Woolley **PRESIDENT** CEO, Research! America



*Georges C. Benjamin, MD SECRETARY Executive Director, American Public Health Association



*Mary J.C. Hendrix, PhD **TREASURER** President and Scientific Director, Ann & Robert H. Lurie Children's Hospital of Chicago Research Center

BOARD MEMBERS

Tenley E. Albright, MD

Director and Founder, MIT Collaborative Initiatives; Visiting Scientist, Massachusetts Institute of Technology; Lecturer in the Program of Surgery, Harvard Medical School

Nancy Brown

Chief Executive Officer, American Heart Association

*Hon. Michael N. Castle

Partner, DLA Piper; U.S. Representative, 1993-2011

Susan Dentzer

Editor-in-Chief, Health Affairs

*Victor J. Dzau, MD

Chancellor for Health Affairs, Duke University; President and CEO, Duke University Health System

Joseph M. Feczko, MD

*Jay A. Gershen, DDS, PhD

President, Northeast Ohio Medical University

†Carol W. Greider, PhD

Professor, The Johns Hopkins University School of Medicine

*Harry Johns

President and Chief Executive Officer, Alzheimer's Association

*Jackie Lovelace Johnson

Chair of the Board, Lovelace Respiratory Research Institute

*Evan Jones

Managing Member, jVen Capital

Elizabeth Baker Keffer

President, Atlantic LIVE and Quartz LIVE; Senior Vice President/Group Publisher - Live Events, Atlantic Media Company

Hon. Patrick Kennedy

U.S. Representative, 1995-2011

Debra R. Lappin, JD

Counsel, FaegreBD Consulting

*Alan I. Leshner, PhD

CEO American Association for the Advancement of Science

*Lucinda Maine, PhD, RPh

Executive Vice President & CEO, American Association of Colleges of Pharmacy

Mark McClellan, MD, PhD

Director, Engelberg Center for Health Care Reform; Senior Fellow, Economic Studies; Leonard D. Schaeffer Chair in Health Policy Studies; Brookings Institution

Hon. Kweisi Mfume

U.S. Representative, 1987-1996

Elizabeth G. Nabel, MD

President, Brigham and Women's Hospital; Professor, Harvard Medical School: Former Director, National Heart, Lung and Blood Institute

*Herbert Pardes, MD

Executive Vice Chairman, Board of Trustees, New York-Presbyterian Hospital

Sudip S. Parikh, PhD

Vice President, Health Policy; Director, Center for Analytics & Public Health; Battelle Health & Life Sciences, Battelle Memorial Institute

John R. Seffrin, PhD

Chief Executive Officer, American Cancer Society

*Larry J. Shapiro, MD

Executive Vice Chancellor for Medical Affairs, Washington University in St. Louis

Ellen Sigal, PhD

Chairperson and Founder, Friends of Cancer Research

Laing Rogers Sisto

Community Leader

*Jack T. Watters, MD

Vice President for External Medical Affairs, Pfizer Inc

Keith Yamamoto, PhD

Vice Chancellor for Research, University of California, San Francisco

Elias A. Zerhouni, MD

President, Global Research & Development, Sanofi

EMERITUS DIRECTORS

William G. Anlyan, MD Dennis A. Ausiello, MD Kenneth I. Berns, MD, PhD William R. Brinkley, PhD Roger J. Bulger, MD G. Steven Burrill Gail H. Cassell, PhD Wendy Chaite, Esq. Jordan J. Cohen, MD Dominick P. DePaola, DDS, PhD Sam Donaldson John P. Donnelly **Robert Dresing** Eugene Garfield, PhD Myron Genel, MD Irma E. Goertzen M.R.C. Greenwood, PhD Elmer E. Huerta, MD, MPH Robert A. Ingram Caroline A. Kovac, PhD Philip R. Lee, MD **Ellen Levine** Constance E. Lieber John P. Margaritis Jewell Jackson McCabe Catherine E. McDermott Donnica L. Moore, MD James E. Mulvihill, DMD William D. Novelli William A. Peck, MD Edward E. Penhoet, PhD William L. Roper, MD, MPH Leon E. Rosenberg, MD Isadore Rosenfeld, MD Raymond R. Sackler, MD Charles A. Sanders, MD Mitchel Sayare, PhD

Carol R. Scheman M. Roy Schwarz, MD Susan C. Scrimshaw, PhD Randolph Siegel Samuel C. Silverstein, MD Hon. Louis Stokes Hon. Louis W. Sullivan, MD Hon. Billy Tauzin Reed V. Tuckson, MD Christopher A. Viehbacher Alan G. Walton, DSc, PhD M. Cass Wheeler John Whitehead **Ruth Wooden** Judy Woodruff James B. Wyngaarden, MD



C. Everett Koop, MD, ScD 1916-2013

IN MEMORIAM

U.S. Surgeon General 1981-1989

Research! America Honorary Director 1989-2013

†Nobel laureate

^{*}Executive Committee Member









RESEARCH AMERICA AN ALLIANCE FOR DISCOVERIES IN HEALTH

1101 King Street, Suite 520 Alexandria, VA 22314

р 703-739-2577 **г** 703-739-2372



www.researchamerica.org/blog





www.researchamerica.org/facebook

